
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a clinical-stage biotechnology company developing therapies for metabolic and endocrine disorders. They have a lead asset, VK2735, which has shown positive results in Phase 2 trials for obesity and has potential for cardiometabolic benefits beyond weight loss. Additionally, they have a diverse pipeline including VK2809 for non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD), positioning the company for potential growth and partnership opportunities. Management has a solid plan in place for expanding access and driving adoption, and with a strong cash balance and positive updates on their clinical programs, Viking Therapeutics is well-positioned for future success in the biopharmaceutical industry.
Bears say
Viking Therapeutics is facing potential legal issues with regards to their license agreement for their lead compounds VK2809 and VK0214, causing uncertainty in the company's ability to develop and commercialize these products. Additionally, their titration schema and treatment period for clinical trials may not be as efficient and cost-effective as originally anticipated, leading to potential delays and increased expenses. Furthermore, there is a risk of unexpected delays or regulatory barriers in their clinical development, and despite having a strong cash runway, there is limited visibility on potential partnership opportunities, creating a negative outlook on the stock.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares